drugset / Trial / NCT05110261
Evaluate the Safety and Efficacy of Nirsevimab in Healthy Preterm and Term Infants in China
RandomizedParallel-groupQuadruple-blindPrevention
Summary
The purpose of this study is to evaluate the Safety and Efficacy of Nirsevimab, in Healthy Preterm and Term Infants in China
Timeline
- Start
- 2021-11-24
- Primary completion
- 2025-11-24
- Completion
- 2025-11-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nirsevimab | Monoclonal antibody | 50 mg | Intramuscular |
| Subject | Nirsevimab | Monoclonal antibody | 100 mg | Intramuscular |